ClinicalTrials.gg
CompletedNCT01651351Updated May 25, 2021Results posted

GLASSIA Infusion Rate Study

A Phase 4 interventional study of Alpha1-proteinase inhibitor and Placebo: Human albumin 2.5% in Alpha1-antitrypsin Deficiency and Healthy Volunteers, sponsored by Baxalta now part of Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-25.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.

Enrollment
11th of 25
30 · median 30
Started
2012
with 2 others
Phase 4
6 of 25
1 open now
Registered
10th of 25
by date
Lead sponsor
4 of 25
Baxalta now part of Shire

Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 11th largest by enrollment, is one of 3 that started in 2012, is one of 6 in phase 4, and was the 10th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alpha 1-Antitrypsin

alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, or all of them as a file.
02

Study summary

The purpose of this study was to generate sufficient safety and tolerability information in support of an increase in the infusion rate of intravenous GLASSIA in the prescribing information from 0.04 to 0.2 mL/kg/min.

Read the detailed description

To achieve proper masking, 30 participants were randomly assigned to receive either GLASSIA at 0.04 mL/kg/min with a simultaneous administration of placebo (2.5% human albumin in normal saline) at 0.2 mL/kg/min (Cohort 1) or GLASSIA at 0.2 mL/kg/min with a simultaneous administration of placebo at 0.04 mL/kg/min (Cohort 2) on Day 1.

Two weeks later (Day 15), the same participants received the second infusion with the opposite rate of GLASSIA infusion and the corresponding masking placebo infusion.

03

Conditions studied

  • Alpha1-antitrypsin Deficiency
  • Healthy Volunteers

Keywords

  • for this study
  • volunteers
  • Focus
  • Condition:
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 65 years of age inclusive, at the time of screening
  • (BMI) in the range of 19.0 to 32.0 kg/m2 (inclusive) and body weight >= 50 kg at the time of screening
  • Healthy subject with no clinical evidence of acute and/or chronic disease and no abnormalities on hematology panel, clinical chemistry panel, urinalysis, or (ECG) at the time of screening
  • Negative drug screen test at screening. Subject must agree to refrain from heavy alcohol consumption (defined as more than 2 drinks per day on a regular basis) and use of narcotic drugs or illegal substances for at least 2 weeks prior to screening and throughout the course of the study. Subject must also agree to drug screen testing at the discretion of the investigator at any time during the course of the study.
  • If female of , subject presents with a negative serum pregnancy test and agrees to employ adequate measures for the duration of the study
  • If male, the subject must agree to use an acceptable form of birth control throughout the study and for at least 90 days after dosing. Additionally, the subject must agree to abstain from sperm donation for 90 days after the last administration of product.
  • Subject is willing and able to comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • Known history of OR positive serological evidence at the time of screening for hepatitis A virus (HAV), virus (HBV), virus (HCV), Parvovirus B19 (PVB19) or (HIV) type 1/2 infection
  • Known history of or adverse reactions (e.g. urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following administration of blood or blood components
  • Documented immunoglobulin A (IgA) deficiency (\<7 mg/dL at screening)
  • Evidence of uncontrolled hypertension (systolic blood pressure of >160 mm Hg, and/or diastolic blood pressure of >100 mm Hg despite anti-hypertensive medications)
  • Subject is nursing or intends to begin nursing during the course of the study
  • Subject has participated in a clinical trial and has received an product within 60 days prior to screening
  • Subject has a planned medical procedure within the study period
  • Any medical, psychiatric, or cognitive illness or recreational drug/alcohol use that, in the opinion of the investigator, may impede the subject's ability to comply with the study procedures, pose increased risk to the subject's safety, or confound the interpretation of study results
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Day 1: * GLASSIA at 0.04 mL/kg/min * Placebo at 0.2 mL/kg/min Day 15: * GLASSIA at 0.2 mL/kg/min * Placebo at 0.04 mL/kg/min

    Biological: Alpha1-proteinase inhibitor · Biological: Placebo: Human albumin 2.5%

  • Experimental
    Cohort 2

    Day 1: * GLASSIA at 0.2 mL/kg/min * Placebo at 0.04 mL/kg/min Day 15: * GLASSIA at 0.04 mL/kg/min * Placebo at 0.2 mL/kg/min

    Biological: Alpha1-proteinase inhibitor · Biological: Placebo: Human albumin 2.5%

Interventions

  • GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.

    Also known as: GLASSIA

  • BiologicalPlacebo: Human albumin 2.5%

    Intravenous administration

06

What researchers measure

Primary outcomes

  1. Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality Assessment)

    Time frame: Day 1 and Day 15

Secondary outcomes

  1. Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 1 Hour of Infusion Completion

    Number of infusions with temporally associated AEs with an onset time during or within 1 hour of infusion completion, regardless of causality assessment

    Time frame: Within 1 hour of infusion completion

  2. Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 24 Hours of Completion of an Infusion

    Number of infusions with temporally associated AEs with an onset time during or within 24 hours of infusion completion, regardless of causality assessment

    Time frame: Within 24 hours of the end of infusion

  3. Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 72 Hours of Completion of an Infusion

    Number of infusions with temporally associated AEs with an onset time during or within 72 hours of infusion completion, regardless of causality assessment

    Time frame: Within 72 hours of the end of infusion

  4. Number of Possibly or Probably Related Adverse Events (AEs) That Began During an Infusion

    Number of AEs that occurred during an infusion and were deemed related to study product administration

    Time frame: Day 1 and Day 15

  5. Number of Possibly or Probably Related Adverse Events That Occurred Between 72 Hours and 14 Days After Infusion

    Number of AEs that occurred between 72 hours and 14 day following an infusion and were deemed related to study product administration

    Time frame: 72 hours post infusion to 14 days post infusion

  6. Number of Participants Testing Positive for Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Parvovirus B19 (PVB19) or Human Immunodeficiency Virus (HIV) Following Treatment With GLASSIA

    Number of participants with seroconversion

    Time frame: 105 days

07

Results

Posted May 29, 2014
Limitations and caveats
Simultaneous infusion of GLASSIA and placebo did not allow adverse events (AEs) to be unquestionably ascribed to either one. Any observed AE which was assessed by the investigator as related to treatment was conservatively attributed to GLASSIA.

Participant flow

Recruitment was conducted in the U.S at 1 study site. The first participant was enrolled in July 2012.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started1515
Completed1515
Not completed00

Outcome measures

PrimaryNumber of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality Assessment)
Time frame:
Day 1 and Day 15
Reported as:
Number · Infusions
Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality Assessment)
InfusionsGLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/MinGLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min
Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality Assessment)00
SecondaryNumber of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 1 Hour of Infusion Completion

Number of infusions with temporally associated AEs with an onset time during or within 1 hour of infusion completion, regardless of causality assessment

Time frame:
Within 1 hour of infusion completion
Reported as:
Number · Infusions
Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 1 Hour of Infusion Completion
InfusionsGLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/MinGLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min
Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 1 Hour of Infusion Completion31
SecondaryNumber of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 24 Hours of Completion of an Infusion

Number of infusions with temporally associated AEs with an onset time during or within 24 hours of infusion completion, regardless of causality assessment

Time frame:
Within 24 hours of the end of infusion
Reported as:
Number · Infusions
Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 24 Hours of Completion of an Infusion
InfusionsGLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/MinGLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min
Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 24 Hours of Completion of an Infusion53
SecondaryNumber of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 72 Hours of Completion of an Infusion

Number of infusions with temporally associated AEs with an onset time during or within 72 hours of infusion completion, regardless of causality assessment

Time frame:
Within 72 hours of the end of infusion
Reported as:
Number · Infusions
Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 72 Hours of Completion of an Infusion
InfusionsGLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/MinGLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min
Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 72 Hours of Completion of an Infusion75
SecondaryNumber of Possibly or Probably Related Adverse Events (AEs) That Began During an Infusion

Number of AEs that occurred during an infusion and were deemed related to study product administration

Time frame:
Day 1 and Day 15
Reported as:
Number · adverse events
Number of Possibly or Probably Related Adverse Events (AEs) That Began During an Infusion
adverse eventsGLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/MinGLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min
Number of Possibly or Probably Related Adverse Events (AEs) That Began During an Infusion10
SecondaryNumber of Possibly or Probably Related Adverse Events That Occurred Between 72 Hours and 14 Days After Infusion

Number of AEs that occurred between 72 hours and 14 day following an infusion and were deemed related to study product administration

Time frame:
72 hours post infusion to 14 days post infusion
Reported as:
Number · adverse events
Number of Possibly or Probably Related Adverse Events That Occurred Between 72 Hours and 14 Days After Infusion
adverse eventsGLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/MinGLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min
Number of Possibly or Probably Related Adverse Events That Occurred Between 72 Hours and 14 Days After Infusion00
SecondaryNumber of Participants Testing Positive for Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Parvovirus B19 (PVB19) or Human Immunodeficiency Virus (HIV) Following Treatment With GLASSIA

Number of participants with seroconversion

Time frame:
105 days
Reported as:
Number · participants
Number of Participants Testing Positive for Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Parvovirus B19 (PVB19) or Human Immunodeficiency Virus (HIV) Following Treatment With GLASSIA
participantsAll Study Participants
HAV0
HBV0
HCV0
PVB190
HIV0

Adverse events

Collected over Throughout the study period of 105 days per participant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GLASSIA Infusion Rate- 0.04 mL/kg/Min—0/30 (0%)8/30 (26.7%)
GLASSIA Infusion Rate- 0.2 mL/kg/Min—0/30 (0%)4/30 (13.3%)
Most frequent other events
Most frequent other events
EventGLASSIA Infusion Rate- 0.04 mL/kg/MinGLASSIA Infusion Rate- 0.2 mL/kg/Min
HeadacheNervous system disorders6/303/30
Back PainMusculoskeletal and connective tissue disorders1/302/30
Pain In ExtremityMusculoskeletal and connective tissue disorders2/300/30
DizzinessNervous system disorders2/301/30

Baseline characteristics

Safety Analysis Set

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Total
Mean27 ± 829 ± 1328 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female347
Male121123
Region of Enrollment
Region of Enrollment(Participants)Cohort 1Cohort 2Total
United States151530
08

Study locations

1 site
  • Overland Park, Kansas 66211, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2012 to primary completion in Jan 2013, 5 months.

Results were first posted in May 2014, 1 year 4 months after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2012
First posted
Jul 27, 2012
StartActual
Jul 31, 2012
Primary completionActual
Jan 16, 2013
CompletionActual
Jan 16, 2013
Results delay requested
Jan 31, 2014
Results first posted
May 29, 2014
Last update
May 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01651351
Responsible party
Sponsor
First posted
Jul 27, 2012
Start date
Jul 31, 2012
Primary completion
Jan 16, 2013
Completion
Jan 16, 2013
Results posted
May 29, 2014
Last update
May 25, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion